We've found 956 total result s

REPRESENT-PF Registry

This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data...

Age: 18 years - 66+

Gender: All

Deucravacitinib in the Treatment of Cicatricial Alopecias

This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). ...

Age: 18 years - 66+

Gender: All

Neutralizing Interleukin (IL)-6

The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major Depressive Disorder (MDD) and evidence of peripheral immune activation. IL-6 is a pro-in...

Age: 18 - 70 years

Gender: All

Evaluating a Prototype CT Scan for ICH Evacuation

The aim of the project is to collect pre-procedural CT scans, intra-procedural post-evacuation scans as well as immediate post-procedural CT scans to evaluate and collect feedback of two Siemens prototypes: 1) perfusion prototype and 2) automatic hemorrhage detection...

Age: 18 years - 66+

Gender: All

A Study of TAK-505 in Adults With Solid Tumors

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or ma...

Age: 18 years - 66+

Gender: All

Imetelstat Combinations in Relapsed AML

IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML. The trial will consist of a safety run-in phase (Part A) employing a 3+3 ...

Age: 18 years - 66+

Gender: All